Darlene Noci - 25 Aug 2025 Form 4 Insider Report for Nuvalent, Inc. (NUVL)

Role: Chief Development Officer
Signature: /s/ Nathan McConarty, attorney-in-fact
Issuer symbol: NUVL
Transactions as of: 25 Aug 2025
Net transactions value: -$187,089
Form type: 4
Filing time: 27 Aug 2025, 16:30:17 UTC
Previous filing: 01 Aug 2025
Next filing: 01 Oct 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Noci Darlene	Chief Development Officer	C/O NUVALENT, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE	/s/ Nathan McConarty, attorney-in-fact	27 Aug 2025	0001862148

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NUVL	Class A Common Stock	Options Exercise	$111,400	+4,000	+8.3%	$27.85	52,034	25 Aug 2025	Direct	F1
transaction	NUVL	Class A Common Stock	Sale	$99,698	-1,348	-2.6%	$73.96	50,686	25 Aug 2025	Direct	F1, F2
transaction	NUVL	Class A Common Stock	Sale	$190,547	-2,543	-5%	$74.93	48,143	25 Aug 2025	Direct	F1, F3
transaction	NUVL	Class A Common Stock	Sale	$8,244	-109	-0.23%	$75.63	48,034	25 Aug 2025	Direct	F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NUVL	Stock Option (Right to Buy)	Options Exercise	$0	-4,000	-3%	$0.000000	130,329	25 Aug 2025	Class A Common Stock	4,000	$27.85	Direct	F1, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2024.
F2	The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.49 to $74.46, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (4) of this Form 4.
F3	The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.49 to $75.48, inclusive.
F4	The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.49 to $75.83, inclusive.
F5	The shares underlying this option have vested or shall vest over the four years following January 6, 2023 in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.